Product
slulimumab
1 clinical trial
1 indication
Indication
Invasive ductal carcinomaClinical trial
Chemoradiotherapy Combined With Slulimumab in the Treatment of First-line Intrahepatic Cholangiocarcinoma: Efficacy and Safety Evaluation of a Phase II Clinical StudyStatus: Not yet recruiting, Estimated PCD: 2026-12-31